Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Gavin Williams, Barby J. Singer, Stephen Ashford, Brian Hoare, Tandy Hastings-Ison, Klemens Fheodoroff, Steffen Berwick, Edwina Sutherland & Bridget Hill. (2022) A synthesis and appraisal of clinical practice guidelines, consensus statements and Cochrane systematic reviews for the management of focal spasticity in adults and children. Disability and Rehabilitation 44:4, pages 509-519.
Read now
Read now
Jolana Markovà, Ute Essner, Bülent Akmaz, Marcella Marinelli, Christiane Trompke, Arnd Lentschat & Carlos Vila. (2019) Sativex® as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial. International Journal of Neuroscience 129:2, pages 119-128.
Read now
Read now
Adrien Gras & Julie Broughton. (2016) A cost-effectiveness model for the use of a cannabis-derived oromucosal spray for the treatment of spasticity in multiple sclerosis. Expert Review of Pharmacoeconomics & Outcomes Research 16:6, pages 771-779.
Read now
Read now
Articles from other publishers (35)
A. Aloy-Duch, M. Santiñà Vila, F. Ramos-D’Angelo, L. Alonso Calo, M.E. Llaneza-Velasco, B. Fortuny-Organs & A. Apezetxea-Celaya. (2023) Desarrollo y validación de estándares para unidades de calidad de centros sanitarios. Journal of Healthcare Quality Research 38:6, pages 366-375.
Crossref
Crossref
Xiaohong Ma, Zhaoyu Yuan, Baicheng Qian, Yunxiang Guan & Baoliang Wang. (2023) Systematic review and meta-analysis of reflexology for people with multiple sclerosis: Systematic Review and Meta-Analysis. Medicine 102:5, pages e32661.
Crossref
Crossref
Darin T Okuda, Daniel Kantor, Mark Jaros, Tina deVries & Samuel Hunter. (2022) Arbaclofen extended-release tablets for spasticity in multiple sclerosis: randomized, controlled clinical trial. Brain Communications 4:6.
Crossref
Crossref
Mauricio F. VillamarRani A. SarkisPage PennellIsaac KohaneBrett K. Beaulieu-Jones. (2022) Severity of Epilepsy and Response to Antiseizure Medications in Individuals With Multiple Sclerosis. Neurology Clinical Practice 12:4.
Crossref
Crossref
Marcel Gebhardt, Peter Kropp, Frank Hoffmann & Uwe K. Zettl. (2022) Headache in Multiple Sclerosis - Pharmacological Aspects. Current Pharmaceutical Design 28:6, pages 445-453.
Crossref
Crossref
Arianna Sartori, Alessandro Dinoto, Lara Stragapede, Giulia Mazzon, Maria Elisa Morelli, Fulvio Pasquin, Alessio Bratina, Antonio Bosco & Paolo Manganotti. (2021) Nabiximols and botulinum toxin injections for patients with multiple sclerosis: efficacy on spasticity and spasms in a single-centre experience. Neurological Sciences 42:12, pages 5037-5043.
Crossref
Crossref
AhmadZaheer Qureshi. (2021) A call to develop standardized guidelines for treatment of spasticity. The Journal of the International Society of Physical and Rehabilitation Medicine 4:1, pages 8.
Crossref
Crossref
Marcello Moccia, Jessica Frau, Antonio Carotenuto, Calogera Butera, Giancarlo Coghe, Pierangelo Barbero, Marco Frontoni, Elisabetta Groppo, Morena Giovannelli, Ubaldo Del Carro, Cristina Inglese, Emma Frasson, Anna Castagna, Maria Buccafusca, Pamela Latino, Caterina Nascimbene, Marcello Romano, Vitalma Liotti, Stefania Lanfranchi, Laura Rapisarda, Silvia Lori, Marcello Esposito, Loredana Maggi, Martina Petracca, Salvatore Lo Fermo, Maria Concetta Altavista, Francesco Bono, Roberto Eleopra & Vincenzo Brescia Morra. (2020) Botulinum toxin for the management of spasticity in multiple sclerosis: the Italian botulinum toxin network study. Neurological Sciences 41:10, pages 2781-2792.
Crossref
Crossref
Rocco Salvatore Calabrò, Margherita Russo, Antonino Naro, Rossella Ciurleo, Giangaetano D'Aleo, Carmela Rifici, Tina Balletta, Cristian La Via, Massimo Destro, Placido Bramanti & Edoardo Sessa. (2020) Nabiximols plus robotic assisted gait training in improving motor performances in people with Multiple Sclerosis.. Multiple Sclerosis and Related Disorders 43, pages 102177.
Crossref
Crossref
Domenico Intiso, Valentina Simone, Michelangelo Bartolo, Andrea Santamato, Maurizio Ranieri, Maria Teresa Gatta & Filomena Di Rienzo. (2020) High Dosage of Botulinum Toxin Type A in Adult Subjects with Spasticity Following Acquired Central Nervous System Damage: Where Are We at?. Toxins 12:5, pages 315.
Crossref
Crossref
Giacomo Lus, Roberto Cantello, Maura Chiara Danni, Agusto Rini, Paola Sarchielli, Tiziana Tassinari & Elisabetta Signoriello. (2018) Palatability and oral cavity tolerability of THC:CBD oromucosal spray and possible improvement measures in multiple sclerosis patients with resistant spasticity: a pilot study. Neurodegenerative Disease Management 8:2, pages 105-113.
Crossref
Crossref
E. V. Kostenko & A. N. Boiko. (2018) Treatment of a spastic increase of muscle tone in multiple sclerosis with botulinum toxin. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 118:7, pages 89.
Crossref
Crossref
JoAnn Tschanz. 2018. Encyclopedia of Clinical Neuropsychology. Encyclopedia of Clinical Neuropsychology
562
563
.
Rainer Ehling, Michael Edlinger, Kay Hermann, Kerstin Dröge, Yvonne Seidinger, Ursula Miller, Hannes Franz Alber & Christian Brenneis. (2017) Successful long-term management of spasticity in patients with multiple sclerosis using a software application (APP): A pilot study. Multiple Sclerosis and Related Disorders 17, pages 15-21.
Crossref
Crossref
Pamela Latino, Letizia Castelli, Luca Prosperini, Maria Rita Marchetti, Carlo Pozzilli & Morena Giovannelli. (2017) Determinants of botulinum toxin discontinuation in multiple sclerosis: a retrospective study. Neurological Sciences 38:10, pages 1841-1848.
Crossref
Crossref
Martin Hlavica, Aro Delparente, Andrin Good, Nicolas Good, Patricia S. Plattner, Maryam S. Seyedsadr, Martin E. Schwab, Dianne P. Figlewicz & Benjamin V. Ineichen. (2017) Intrathecal insulin-like growth factor 1 but not insulin enhances myelin repair in young and aged rats. Neuroscience Letters 648, pages 41-46.
Crossref
Crossref
Antonino Naro, Antonino Leo, Margherita Russo, Carmela Casella, Antonio Buda, Aurelio Crespantini, Bruno Porcari, Luigi Carioti, Luana Billeri, Alessia Bramanti, Placido Bramanti & Rocco Salvatore Calabrò. (2017) Breakthroughs in the spasticity management: Are non-pharmacological treatments the future?. Journal of Clinical Neuroscience 39, pages 16-27.
Crossref
Crossref
Gillian M. Keating. (2017) Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex®): A Review in Multiple Sclerosis-Related Spasticity. Drugs 77:5, pages 563-574.
Crossref
Crossref
Benjamin V Ineichen, Lisa Schnell, Miriam Gullo, Julia Kaiser, Marc P Schneider, Alice C Mosberger, Nicolas Good, Michael Linnebank & Martin E Schwab. (2016) Direct, long-term intrathecal application of therapeutics to the rodent CNS. Nature Protocols 12:1, pages 104-121.
Crossref
Crossref
Bruno Brochet, Christine Lebrun-Frénay, Jérôme de Sèze, Hélène Zéphir, E. Allart, B. Audoin, X. Ayrignac, C. Bensa, A. Blanchard-Dauphin, D. Brassat, C. Carra-Dallière, P. Clavelou, M. Cohen, A. Créange, N. Collongues, M. Debouverie, G. Defer, M. de Sèze, C. Donzé, G. Edan, A. Fromont, X. Gamé, O. Gout, C. Guillon, C. Harand, B. Jenny, P. Labauge, P.-H. Lalive, E. Le Page, P. Marque, L. Michel, X. Moisset, J.-C. Ouallet, O. Outteryck, F. Pelé, J. Pelletier, S. Pittion-Vouyovitch, A.-L. Ramelli, A. Ruet, E. Thouvenot, D. Veillard, C. Vignal-Clermont & S. Vukusic. 2017. La Sclérose en Plaques - Clinique et Thérapeutique. La Sclérose en Plaques - Clinique et Thérapeutique
145
216
.
Dirk Dressler, Roongroj Bhidayasiri, Saeed Bohlega, Abderrahmane Chahidi, Tae Mo Chung, Markus Ebke, L. Jorge Jacinto, Ryuji Kaji, Serdar Koçer, Petr Kanovsky, Federico Micheli, Olga Orlova, Sebastian Paus, Zvezdan Pirtosek, Maja Relja, Raymond L. Rosales, José Alberto Sagástegui-Rodríguez, Paul W. Schoenle, Gholam Ali Shahidi, Sofia Timerbaeva, Uwe Walter & Fereshte Adib Saberi. (2016) Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force. Journal of Neurology 264:1, pages 112-120.
Crossref
Crossref
JoAnn Tschanz. 2018. Encyclopedia of Clinical Neuropsychology. Encyclopedia of Clinical Neuropsychology
1
2
.
Francois Bethoux & Ruth Ann Marrie. (2016) A Cross-Sectional Study of the Impact of Spasticity on Daily Activities in Multiple Sclerosis. The Patient - Patient-Centered Outcomes Research 9:6, pages 537-546.
Crossref
Crossref
Giovanna Squintani, Francesco Donato, Mara Turri, Luciano Deotto, Francesco Teatini, Giuseppe Moretto & Roberto Erro. (2016) Cortical and spinal excitability in patients with multiple sclerosis and spasticity after oromucosal cannabinoid spray. Journal of the Neurological Sciences 370, pages 263-268.
Crossref
Crossref
Philip Brenner, Ellenor Mittendorfer-Rutz, Jussi Jokinen, Kristina Alexanderson, Jan Hillert & Petter Tingh?g. (2016) Prescribed psychiatric medication among multiple sclerosis patients before and after disability pension: a register study with matched controls. Social Psychiatry and Psychiatric Epidemiology 51:7, pages 1047-1054.
Crossref
Crossref
Anton Bespalov, Liudmila Mus & Edwin Zvartau. (2016) Preclinical models of muscle spasticity: valuable tools in the development of novel treatment for neurological diseases and conditions. Naunyn-Schmiedeberg's Archives of Pharmacology 389:5, pages 457-466.
Crossref
Crossref
Patrick Vermersch. (2015) Advances in the management of MS symptoms: recently proposed clinical management algorithms. Neurodegenerative Disease Management 5:6s, pages 23-26.
Crossref
Crossref
Rainel Sánchez-de la Rosa, Laura García-Bujalance & José Meca-Lallana. (2015) Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study. Health Economics Review 5:1.
Crossref
Crossref
VL Stevenson, A Gras, JI Bárdos & J Broughton. (2015) The high cost of spasticity in multiple sclerosis to individuals and society. Multiple Sclerosis Journal 21:12, pages 1583-1592.
Crossref
Crossref
Jose Eustasio Meca‐Lallana, Rocío Hernández‐Clares & Ester Carreón‐Guarnizo. (2015) Spasticity in multiple sclerosis and role of glatiramer acetate treatment. Brain and Behavior 5:9.
Crossref
Crossref
Rebecca A. Harrison & Thalia S. Field. (2015) Post Stroke Pain: Identification, Assessment, and Therapy. Cerebrovascular Diseases 39:3-4, pages 190-201.
Crossref
Crossref
Michelle H. Cameron, Francois Bethoux, Nina Davis & Meredith Frederick. (2014) Botulinum Toxin for Symptomatic Therapy in Multiple Sclerosis. Current Neurology and Neuroscience Reports 14:8.
Crossref
Crossref
Kornelia Tekes. (2014) Basic Aspects of the Pharmacodynamics of Tolperisone, A Widely Applicable Centrally Acting Muscle Relaxant. The Open Medicinal Chemistry Journal 8:1, pages 17-22.
Crossref
Crossref
Yahiya Y. Syed, Kate McKeage & Lesley J. Scott. (2014) Delta-9-Tetrahydrocannabinol/Cannabidiol (Sativex®): A Review of Its Use in Patients with Moderate to Severe Spasticity Due to Multiple Sclerosis. Drugs 74:5, pages 563-578.
Crossref
Crossref
Darin T. Okuda, Daniel Kantor, Mark Jaros, Tina deVries & Samuel Hunter. (2022) Arbaclofen Extended-Release Tablets for the Treatment of Spasticity in Patients with Multiple Sclerosis: A Randomized, Placebo-Controlled Clinical Trial. SSRN Electronic Journal.
Crossref
Crossref